Division of Teva Pharmaceutical Industries Ltd.
Latest From Mepha LLC
OTC ranitidine products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.
Janssen paid $150 million for Pharmacyclics’ Phase II Btk inhibitor, 2011’s largest up-front for a single asset. Alexion acquired rare disease developer Enobia for just over $1 billion in up-front and earn-out payments. Biopharma fundraising dipped in December, while device financing increased for the second month in a row.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Teva brought in Cephalon and a vastly expanded Japanese operation in 2011, and now the company expects to carve out local deals in new markets, execs tell investors during the annual JP Morgan Healthcare Conference.
- Controlled Release
- Topical Delivery
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Mepha AG
- Mepha Pharma AG
- Western Europe
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Andreas Bosshard, Gen. Mgr.
- Contact Info
Phone: (41) 61 701 4343
P.O. Box 445 Aesch, CH-4147
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.